Citeline Releases "Clinical Trials 2025 Annual Review" and "Clinical Trials 2025 Annual Review Japanese Summary Edition"

July 1, 2026 – Citeline (a Norstella Group company), which provides insights for the pharmaceutical and biopharmaceutical industries, has released the "Clinical Trials 2025 Annual Review," summarizing clinical trial trends in 2025. A "Clinical Trials 2025 Annual Review Japanese Summary Edition," compiling key points, has also been published.

Key Findings

2025 saw a decrease in the total number of clinical trials, but an improvement in success rates and quality of late-stage trials, marking a year of structural transformation from "quantity to quality."

Completed trials decreased by 11% year-on-year to 4,364

Success rates improved

Oncology remains the largest therapeutic area

Metabolic and endocrine disorders entered the top 3 for the first time

GLP-1 related research expanded (focusing on obesity and type 2 diabetes)

Infectious disease and vaccine trials decreased (post-pandemic shifts)

Pipelines expanded, with an increase in novel mechanisms of action

*Source: Citeline, “Annual Completed Clinical Trials Report 2026 Edition” (Analysis of 2025 performance)

Implications for the Industry

Despite a 11% year-on-year decrease in clinical trial numbers in 2025, the industry demonstrated a trend towards "quality over quantity," with rising success rates and an increase in positive pivotal trials.

Furthermore, pipeline expansion is progressing, particularly in oncology and metabolic/endocrine areas, confirming advancements in the development of new medicines.

On the other hand, regulatory changes, funding environments, and geopolitical factors are influencing clinical trial activities, and these external factors may impact future trends.

*The content herein is an extraction of publicly available information from the report and analysis/consideration based on our database, and does not guarantee future results or market trends. Interpretation may also involve certain assumptions and limitations.

Clinical Trials 2025 Annual Review Japanese Summary Edition

Access the Japanese summary (single slide format) for a concise overview of key data here *Available for viewing on the page or for PDF download.

View Details

Clinical Trials 2025 Annual Review (Full English Edition)

Access detailed analysis (by disease, company, pipeline trends) here

*Available for viewing on the page or for PDF download.

View Details

About Citeline

Citeline is a global intelligence brand providing data and analytics on research and development, clinical trials, regulatory affairs, and commercialization for the pharmaceutical and biotechnology industries. We specialize in supporting strategic development planning based on global development overviews and competitive pipelines, as well as providing comprehensive support from trial design to patient recruitment using U.S. pipeline, trial, principal investigator, and real-world data.

View Details

PR Contact

https://www.citeline.com/ja-jp/contact-us

Evaluate Japan Inc.

APAC Marketing Department

This press release may be freely reproduced and published.

We would appreciate it if you could cooperate as much as possible by clearly stating the source and providing a link.

*Please feel free to contact us for inquiries regarding interviews.